NL-OMON46244已完成不适用
A first-in-human, randomized, dose-Escalation, double-blind, placebo-controlled study to assess safety, tolerability and pharmacokinetics of APX001 administered by intravenous infusion to healthy subjects. - APX001 First in human study.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy male or female volunteers
- •18 - 55 years, inclusive
- •BMI 18.0 - 30.0 kilogram/meter2
- •non smoking
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
进行中（未招募）
1 期
First-in-human study of ATR inhibitor BAY 1895344 in patients with advanced solid tumors and lymphomas.EUCTR2016-004484-39-GBBayer AG910
进行中（未招募）
1 期
First-in-human study of ATR inhibitor BAY 1895344 in patients with advanced solid tumors and lymphomas.Part A: Histologically confirmed solid tumors and lymphomas, J-arm : Advanced solid tumorsPart B: a) DDR defects putative biomarker-positive advanced solid tumors: i) CRPCii) lung cancer, including adenocarcinoma, squamous carcinoma, or small cell lung canceriii) colorectal canceriv) gynecological tumors. b) Advanced mantle cell lymphoma. Diffuse large B cell lymphoma. Part C: CRPC with symptomatic confirmed bone metastases and no known visceral metastatic disease.MedDRA version: 20.0Level: PTClassification code 10028997Term: Neoplasm malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-004484-39-FRBayer AG320
已完成
1 期
First-in-human study of ATR inhibitor BAY1895344 in patients with advanced solid tumors and lymphomas.JPRN-jRCT2080223941Bayer Yakuhin, Ltd20
招募中
1 期
First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN)Acute lymphocytic leukaemia- Acute myeloid leukaemia refractory - Myelodysplastic syndrome - Blastic plasmacytoid dendritic cell neoplasiaMedDRA version: 21.0Level: PTClassification code: 10003917Term: B-cell type acute leukaemia Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10075460Term: Blastic plasmacytoid dendritic cell neoplasia Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10028533Term: Myelodysplastic syndrome Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10081513Term: Acute myeloid leukaemia refractory Class: 100000004864CTIS2023-508357-58-00Sanofi-Aventis Recherche & Developpement143
招募中
2 期
An open-label, first-in-human, dose-escalation/expansion study of SAR443579 administered as single agent by intravenous infusion in adult and pediatric participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS) or blastic plasmacytoid dendritic cell neoplasm (BPDCN)Acute leukemiaNL-OMON55908Sanofi BV18